Tiziana Life Sciences Ltd (TLSA) - Form 20-F Summary
Business Context and Reporting Period
Company: Tiziana Life Sciences Ltd (Bermuda-incorporated, NASDAQ: TLSA)
Reporting Period: Fiscal Year Ended December 31, 2024
Business Model: Clinical-stage biotechnology company focused on developing immunotherapies for neurodegenerative and neuroinflammatory diseases. The company operates a lean, virtual R&D model.
Lead Asset: Foralumab (TZLS-401), a fully human anti-CD3 monoclonal antibody, currently being developed via intranasal administration for Secondary Progressive Multiple Sclerosis (SPMS), Alzheimer's Disease, and ALS.
Accounting Basis: International Financial Reporting Standards (IFRS); Presentation currency is U.S. Dollars.
Key Financial Metrics (Year Ended Dec 31, 2024)
| Metric | 2024 (in thousands) | 2023 (in thousands) |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(11,863) | $(17,691) |
| Operating Expenses | $(15,794) | $(17,984) |
| - Research & Development | $(5,229) | $(8,113) |
| - General & Administrative | $(10,565) | $(9,871) |
| Cash and Cash Equivalents | $3,724 | $1,183 |
| Total Assets | $11,284 | $12,184 |
| Total Liabilities | $7,348 | $6,648 |
| Shareholders' Equity | $3,936 | $5,534 |
| Outstanding Shares | 111,462,617 | 103,087,744 |
Note: The company reported a significant income tax credit of $4.88 million in 2024, primarily due to the receipt of R&D tax credits for prior periods (2022 and 2023).
Material Changes vs. Prior Period
- Reduced Net Loss: Net loss decreased by approximately $5.8 million (32%) compared to 2023, driven by a $4.9 million R&D tax credit and a reduction in R&D expenses.
- R&D Expense Reduction: R&D expenses fell by $2.9 million (35%) to $5.2 million. This was due to the cessation of focus on the IL6-R program (TZLS-501) and reduced license fee expenditures following renegotiations.
- Increased G&A Expenses: General and administrative expenses increased by $0.7 million to $10.6 million, attributed to higher payroll and consulting costs.
- Investment Fair Value Loss: The company recognized a $1.76 million loss on the fair value of investments in related parties (Accustem Sciences Inc. and Okyo Pharma Ltd.), compared to a $0.4 million loss in 2023.
- Liquidity Improvement: Cash and cash equivalents increased from $1.2 million to $3.7 million, supported by $4.5 million in net cash provided by financing activities (fundraising and option exercises).
Guidance, Outlook, and Risks
Outlook and Strategy:
- Focus on Foralumab: The company has deprioritized other assets to focus resources on intranasal Foralumab for SPMS, Alzheimer's, and ALS.
- Clinical Progress: A Phase 2a trial for SPMS is underway with top-line results anticipated in Q4 2025. The FDA granted Fast Track designation for Foralumab in SPMS in July 2024. An Expanded Access Program (EAP) for SPMS has been expanded to 30 patients.
- Funding Needs: Management forecasts that current cash reserves will be utilized by March 2026 without additional financing. The company is actively pursuing equity fundraising, cost reductions, and deferred payments to extend its runway.
Material Risks and Contingencies:
- Going Concern Uncertainty: The independent auditor (PKF Littlejohn) has issued a "Going Concern" opinion, noting substantial doubt about the company's ability to continue as a going concern due to recurring losses and the need for significant capital to fund clinical trials.
- Internal Control Weakness: Management identified a material weakness in internal controls related to the failure to timely develop and communicate an employee handbook.
- Regulatory Compliance: The company disclosed that it sold approximately 2.6 million shares ($3.6 million) under an expired shelf registration statement in early 2025. These sales may be subject to rescission rights by purchasers and potential regulatory penalties.
- Intellectual Property: Key patents for Foralumab are set to expire in 2025, though the company holds newer patents extending protection to 2037-2046 for specific formulations and uses.
Key Facts for Investor Verification
- Cash Runway: Verify the company's ability to secure additional funding before March 2026 to avoid insolvency or forced asset sales.
- Regulatory Status: Monitor the outcome of the SEC review regarding the sale of shares under an expired registration statement and any potential penalties or rescission claims.
- Clinical Trial Data: Await top-line results from the Phase 2a SPMS trial (expected Q4 2025) to validate the efficacy of intranasal Foralumab.
- Internal Controls: Assess the remediation plan for the identified material weakness in internal controls over financial reporting.
- Patent Expiry: Confirm the status of patent extensions or new filings to protect the core Foralumab technology beyond the 2025 expiration of foundational patents.